Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
Subscribe

Logo for

Science 303 (5665): 1800-1805

Copyright © 2004 by the American Association for the Advancement of Science

Protein Kinase Inhibitors: Insights into Drug Design from Structure

Martin E. M. Noble,* Jane A. Endicott,* Louise N. Johnson*{dagger}

Abstract: Protein kinases are targets for treatment of a number of diseases. This review focuses on kinase inhibitors that are in the clinic or in clinical trials and for which structural information is available. Structures have informed drug design and have illuminated the mechanism of inhibition. We review progress with the receptor tyrosine kinases (growth factor receptors EGFR, VEGFR, and FGFR) and nonreceptor tyrosine kinases (Bcr-Abl), where advances have been made with cancer therapeutic agents such as Herceptin and Gleevec. Among the serine-threonine kinases, p38, Rho-kinase, cyclin-dependent kinases, and Chk1 have been targeted with productive results for inflammation and cancer. Structures have provided insights into targeting the inactive or active form of the kinase, for targeting the global constellation of residues at the ATP site or less conserved additional pockets or single residues, and into targeting noncatalytic domains.

Laboratory of Molecular Biophysics, Department of Biochemistry, Rex Richards Building, University of Oxford, Oxford 3X2 3QU, UK.

Back to Top

* These authors contributed equally to this work.

{dagger} To whom correspondence should be addressed. E-mail: louise{at}biop.ox.ac.uk

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Induction of Endoplasmic Reticulum Stress by Sorafenib and Activation of NF-{kappa}B by Lestaurtinib as a Novel Resistance Mechanism in Hodgkin Lymphoma Cell Lines.
M. S. Holz, A. Janning, C. Renne, S. Gattenlohner, T. Spieker, and A. Brauninger (2013)
Mol. Cancer Ther. 12, 173-183
   Abstract »    Full Text »    PDF »
KIDFamMap: a database of kinase-inhibitor-disease family maps for kinase inhibitor selectivity and binding mechanisms.
Y.-Y. Chiu, C.-T. Lin, J.-W. Huang, K.-C. Hsu, J.-H. Tseng, S.-R. You, and J.-M. Yang (2013)
Nucleic Acids Res. 41, D430-D440
   Abstract »    Full Text »    PDF »
Effect of Connective Tissue Growth Factor on Protein Kinase Expression and Activity in Human Corneal Fibroblasts.
S. S. Radhakrishnan, T. D. Blalock, P. M. Robinson, G. Secker, J. Daniels, G. R. Grotendorst, and G. S. Schultz (2012)
Invest. Ophthalmol. Vis. Sci. 53, 8076-8085
   Abstract »    Full Text »    PDF »
Mechanism of Drug Efficacy Within the EGF Receptor Revealed by Microsecond Molecular Dynamics Simulation.
S. Wan, D. W. Wright, and P. V. Coveney (2012)
Mol. Cancer Ther. 11, 2394-2400
   Abstract »    Full Text »    PDF »
Detection of a rare BCR-ABL tyrosine kinase fusion protein in H929 multiple myeloma cells using immunoprecipitation (IP)-tandem mass spectrometry (MS/MS).
S. B. Breitkopf, M. Yuan, G. A. Pihan, and J. M. Asara (2012)
PNAS 109, 16190-16195
   Abstract »    Full Text »    PDF »
Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
S.-W. Huang, J.-C. Lien, S.-C. Kuo, and T.-F. Huang (2012)
Carcinogenesis 33, 1022-1030
   Abstract »    Full Text »    PDF »
Aminoglycoside 2''-Phosphotransferase IIIa (APH(2'')-IIIa) Prefers GTP over ATP: STRUCTURAL TEMPLATES FOR NUCLEOTIDE RECOGNITION IN THE BACTERIAL AMINOGLYCOSIDE-2'' KINASES.
C. A. Smith, M. Toth, H. Frase, L. J. Byrnes, and S. B. Vakulenko (2012)
J. Biol. Chem. 287, 12893-12903
   Abstract »    Full Text »    PDF »
Molecular Mechanism of Selectivity among G Protein-Coupled Receptor Kinase 2 Inhibitors.
D. M. Thal, R. Y. Yeow, C. Schoenau, J. Huber, and J. J. G. Tesmer (2011)
Mol. Pharmacol. 80, 294-303
   Abstract »    Full Text »    PDF »
Polo-like kinases and DNA damage checkpoint: beyond the traditional mitotic functions.
E. M. Bahassi (2011)
Exp Biol Med 236, 648-657
   Abstract »    Full Text »    PDF »
Engineered Conformation-dependent VEGF Peptide Mimics Are Effective in Inhibiting VEGF Signaling Pathways.
D. Vicari, K. C. Foy, E. M. Liotta, and P. T. P. Kaumaya (2011)
J. Biol. Chem. 286, 13612-13625
   Abstract »    Full Text »    PDF »
Multidomain assembled states of Hck tyrosine kinase in solution.
S. Yang, L. Blachowicz, L. Makowski, and B. Roux (2010)
PNAS 107, 15757-15762
   Abstract »    Full Text »    PDF »
Nanopore-Based Devices for Bioanalytical Applications.
R. Mulero, A. S. Prabhu, K. J. Freedman, and M. J. Kim (2010)
Journal of Laboratory Automation 15, 243-252
   Abstract »    Full Text »    PDF »
The novel mouse Polo-like kinase 5 responds to DNA damage and localizes in the nucleolus.
Z. Andrysik, W. Z. Bernstein, L. Deng, D. L. Myer, Y. Q. Li, J. A. Tischfield, P. J. Stambrook, and E. M. Bahassi (2010)
Nucleic Acids Res. 38, 2931-2943
   Abstract »    Full Text »    PDF »
Evolution of CASK into a Mg2+-Sensitive Kinase.
K. Mukherjee, M. Sharma, R. Jahn, M. C. Wahl, and T. C. Sudhof (2010)
Science Signaling 3, ra33
   Abstract »    Full Text »    PDF »
Novel angiogenesis inhibitory activity in cinnamon extract blocks VEGFR2 kinase and downstream signaling.
J. Lu, K. Zhang, S. Nam, R. A. Anderson, R. Jove, and W. Wen (2010)
Carcinogenesis 31, 481-488
   Abstract »    Full Text »    PDF »
Kinase selectivity potential for inhibitors targeting the ATP binding site: a network analysis.
D. Huang, T. Zhou, K. Lafleur, C. Nevado, and A. Caflisch (2010)
Bioinformatics 26, 198-204
   Abstract »    Full Text »    PDF »
The renal WNK kinase pathway: a new link to hypertension.
E. J. Hoorn, N. van der Lubbe, and R. Zietse (2009)
Nephrol. Dial. Transplant. 24, 1074-1077
   Full Text »    PDF »
Mapping the conformational transition in Src activation by cumulating the information from multiple molecular dynamics trajectories.
S. Yang, N. K. Banavali, and B. Roux (2009)
PNAS 106, 3776-3781
   Abstract »    Full Text »    PDF »
A conserved protonation-dependent switch controls drug binding in the Abl kinase.
Y. Shan, M. A. Seeliger, M. P. Eastwood, F. Frank, H. Xu, M. O Jensen, R. O. Dror, J. Kuriyan, and D. E. Shaw (2009)
PNAS 106, 139-144
   Abstract »    Full Text »    PDF »
Inhibition of CDKS by roscovitine suppressed LPS-induced {middle dot}NO production through inhibiting NF{kappa}B activation and BH4 biosynthesis in macrophages.
J. Du, N. Wei, T. Guan, H. Xu, J. An, K. A. Pritchard Jr., and Y. Shi (2009)
Am J Physiol Cell Physiol 297, C742-C749
   Abstract »    Full Text »    PDF »
Imatinib mesylate inhibits in vitro and ex vivo biological responses related to vascular occlusion in giant cell arteritis.
E Lozano, M Segarra, A Garcia-Martinez, J Hernandez-Rodriguez, and M C Cid (2008)
Ann Rheum Dis 67, 1581-1588
   Abstract »    Full Text »    PDF »
Meriolins, a New Class of Cell Death Inducing Kinase Inhibitors with Enhanced Selectivity for Cyclin-Dependent Kinases.
K. Bettayeb, O. M. Tirado, S. Marionneau-Lambot, Y. Ferandin, O. Lozach, J. C. Morris, S. Mateo-Lozano, P. Drueckes, C. Schachtele, M. H.G. Kubbutat, et al. (2007)
Cancer Res. 67, 8325-8334
   Abstract »    Full Text »    PDF »
Mechanistic insight into the dominant mode of the Parkinson's disease-associated G2019S LRRK2 mutation.
B. Luzon-Toro, E. R. de la Torre, A. Delgado, J. Perez-Tur, and S. Hilfiker (2007)
Hum. Mol. Genet. 16, 2031-2039
   Abstract »    Full Text »    PDF »
Structural basis for the specific inhibition of protein kinase G, a virulence factor of Mycobacterium tuberculosis.
N. Scherr, S. Honnappa, G. Kunz, P. Mueller, R. Jayachandran, F. Winkler, J. Pieters, and M. O. Steinmetz (2007)
PNAS 104, 12151-12156
   Abstract »    Full Text »    PDF »
Allosteric regulation of an essential trypanosome polyamine biosynthetic enzyme by a catalytically dead homolog.
E. K. Willert, R. Fitzpatrick, and M. A. Phillips (2007)
PNAS 104, 8275-8280
   Abstract »    Full Text »    PDF »
Cutting Edge: IL-1 Receptor-Associated Kinase 4 Structures Reveal Novel Features and Multiple Conformations.
A. Kuglstatter, A. G. Villasenor, D. Shaw, S. W. Lee, S. Tsing, L. Niu, K. W. Song, J. W. Barnett, and M. F. Browner (2007)
J. Immunol. 178, 2641-2645
   Abstract »    Full Text »    PDF »
Three Mechanistically Distinct Kinase Assays Compared: Measurement of Intrinsic ATPase Activity Identified the Most Comprehensive Set of ITK Inhibitors.
M. A. Kashem, R. M. Nelson, J. D. Yingling, S. S. Pullen, A. S. Prokopowicz III, J. W. Jones, J. P. Wolak, G. R. Rogers, M. M. Morelock, R. J. Snow, et al. (2007)
J Biomol Screen 12, 70-83
   Abstract »    PDF »
The gatekeeper residue controls autoactivation of ERK2 via a pathway of intramolecular connectivity.
M. A. Emrick, T. Lee, P. J. Starkey, M. C. Mumby, K. A. Resing, and N. G. Ahn (2006)
PNAS 103, 18101-18106
   Abstract »    Full Text »    PDF »
Structure and Chemical Inhibition of the RET Tyrosine Kinase Domain.
P. P. Knowles, J. Murray-Rust, S. Kjaer, R. P. Scott, S. Hanrahan, M. Santoro, C. F. Ibanez, and N. Q. McDonald (2006)
J. Biol. Chem. 281, 33577-33587
   Abstract »    Full Text »    PDF »
JX401, A p38{alpha} Inhibitor Containing a 4-Benzylpiperidine Motif, Identified via a Novel Screening System in Yeast.
Y. Friedmann, A. Shriki, E. R. Bennett, S. Golos, R. Diskin, I. Marbach, E. Bengal, and D. Engelberg (2006)
Mol. Pharmacol. 70, 1395-1405
   Abstract »    Full Text »    PDF »
Dynamic Profiling of the Post-translational Modifications and Interaction Partners of Epidermal Growth Factor Receptor Signaling after Stimulation by Epidermal Growth Factor Using Extended Range Proteomic Analysis (ERPA).
S.-L. Wu, J. Kim, R. W. Bandle, L. Liotta, E. Petricoin, and B. L. Karger (2006)
Mol. Cell. Proteomics 5, 1610-1627
   Abstract »    Full Text »    PDF »
Structural Analysis of Protein Kinase A Mutants with Rho-kinase Inhibitor Specificity.
S. Bonn, S. Herrero, C. B. Breitenlechner, A. Erlbruch, W. Lehmann, R. A. Engh, M. Gassel, and D. Bossemeyer (2006)
J. Biol. Chem. 281, 24818-24830
   Abstract »    Full Text »    PDF »
Role of the Activation Loop Tyrosines in Regulation of the Insulin-like Growth Factor I Receptor-tyrosine Kinase.
W. Li and W. T. Miller (2006)
J. Biol. Chem. 281, 23785-23791
   Abstract »    Full Text »    PDF »
Src protein tyrosine kinase family and acute inflammatory responses.
D. Okutani, M. Lodyga, B. Han, and M. Liu (2006)
Am J Physiol Lung Cell Mol Physiol 291, L129-L141
   Abstract »    Full Text »    PDF »
kinDOCK: a tool for comparative docking of protein kinase ligands..
L. Martin, V. Catherinot, and G. Labesse (2006)
Nucleic Acids Res. 34, W325-W329
   Abstract »    Full Text »    PDF »
A Generic, Homogenous Method for Measuring Kinase and Inhibitor Activity via Adenosine 5'-Diphosphate Accumulation.
N. W. Charter, L. Kauffman, R. Singh, and R. M. Eglen (2006)
J Biomol Screen 11, 390-399
   Abstract »    PDF »
A New Strategy of High-Speed Screening and Quantitative Structure-Activity Relationship Analysis to Evaluate Human ATP-Binding Cassette Transporter ABCG2-Drug Interactions.
H. Saito, H. Hirano, H. Nakagawa, T. Fukami, K. Oosumi, K. Murakami, H. Kimura, T. Kouchi, M. Konomi, E. Tao, et al. (2006)
J. Pharmacol. Exp. Ther. 317, 1114-1124
   Abstract »    Full Text »    PDF »
Cell Cycle- and Apoptosis-regulatory Protein-1 Is Involved in Apoptosis Signaling by Epidermal Growth Factor Receptor.
A. K. Rishi, L. Zhang, Y. Yu, Y. Jiang, J. Nautiyal, A. Wali, J. A. Fontana, E. Levi, and A. P. N. Majumdar (2006)
J. Biol. Chem. 281, 13188-13198
   Abstract »    Full Text »    PDF »
Rapid selection of specific MAP kinase-binders from designed ankyrin repeat protein libraries.
P. Amstutz, H. Koch, H. K. Binz, S. A. Deuber, and A. Pluckthun (2006)
Protein Eng. Des. Sel. 19, 219-229
   Abstract »    Full Text »    PDF »
A Growth-suppressive Function for the c-Fes Protein-Tyrosine Kinase in Colorectal Cancer.
F. J. Delfino, H. Stevenson, and T. E. Smithgall (2006)
J. Biol. Chem. 281, 8829-8835
   Abstract »    Full Text »    PDF »
Unique structural determinants for stat3 recruitment and activation by the granulocyte colony-stimulating factor receptor at phosphotyrosine ligands 704 and 744..
H. Shao, X. Xu, N. Jing, and D. J. Tweardy (2006)
J. Immunol. 176, 2933-2941
   Abstract »    Full Text »    PDF »
Oncogenic BRAF Is Required for Tumor Growth and Maintenance in Melanoma Models.
K. P. Hoeflich, D. C. Gray, M. T. Eby, J. Y. Tien, L. Wong, J. Bower, A. Gogineni, J. Zha, M. J. Cole, H. M. Stern, et al. (2006)
Cancer Res. 66, 999-1006
   Abstract »    Full Text »    PDF »
Structure of the Kinase Domain of an Imatinib-Resistant Abl Mutant in Complex with the Aurora Kinase Inhibitor VX-680.
M. A. Young, N. P. Shah, L. H. Chao, M. Seeliger, Z. V. Milanov, W. H. Biggs III, D. K. Treiber, H. K. Patel, P. P. Zarrinkar, D. J. Lockhart, et al. (2006)
Cancer Res. 66, 1007-1014
   Abstract »    Full Text »    PDF »
Mutational analysis of the SH2-kinase linker region of Bruton's tyrosine kinase defines alternative modes of regulation for cytoplasmic tyrosine kinase families.
S. Guo, M. I. Wahl, and O. N. Witte (2006)
Int. Immunol. 18, 79-87
   Abstract »    Full Text »    PDF »
Characterization of an ERK-binding Domain in Microphthalmia-associated Transcription Factor and Differential Inhibition of ERK2-mediated Substrate Phosphorylation.
D. M. Molina, S. Grewal, and L. Bardwell (2005)
J. Biol. Chem. 280, 42051-42060
   Abstract »    Full Text »    PDF »
Alterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE/Ref-1) in human melanoma and identification of the therapeutic potential of resveratrol as an APE/Ref-1 inhibitor.
S. Yang, K. Irani, S. E. Heffron, F. Jurnak, and F. L. Meyskens Jr. (2005)
Mol. Cancer Ther. 4, 1923-1935
   Abstract »    Full Text »    PDF »
Identification of an Inactivating Cysteine Switch in Protein Kinase C{varepsilon}, a Rational Target for the Design of Protein Kinase C{varepsilon}-Inhibitory Cancer Therapeutics.
F. Chu, J. M. Koomen, R. Kobayashi, and C. A. O'Brian (2005)
Cancer Res. 65, 10478-10485
   Abstract »    Full Text »    PDF »
Activated Tyrosine Kinase Ack1 Promotes Prostate Tumorigenesis: Role of Ack1 in Polyubiquitination of Tumor Suppressor Wwox.
N. P. Mahajan, Y. E. Whang, J. L. Mohler, and H. S. Earp (2005)
Cancer Res. 65, 10514-10523
   Abstract »    Full Text »    PDF »
Small molecule intervention in microtubule-associated human disease.
J. M. Gerdes and N. Katsanis (2005)
Hum. Mol. Genet. 14, R291-R300
   Abstract »    Full Text »    PDF »
Roscovitine Targets, Protein Kinases and Pyridoxal Kinase.
S. Bach, M. Knockaert, J. Reinhardt, O. Lozach, S. Schmitt, B. Baratte, M. Koken, S. P. Coburn, L. Tang, T. Jiang, et al. (2005)
J. Biol. Chem. 280, 31208-31219
   Abstract »    Full Text »    PDF »
Pharmacogenetics in drug development.
A. D. McCarthy, J. L. Kennedy, and L. T. Middleton (2005)
Phil Trans R Soc B 360, 1579-1588
   Abstract »    Full Text »    PDF »
A Cell-permeable, Activity-based Probe for Protein and Lipid Kinases.
M.-c. Yee, S. C. Fas, M. M. Stohlmeyer, T. J. Wandless, and K. A. Cimprich (2005)
J. Biol. Chem. 280, 29053-29059
   Abstract »    Full Text »    PDF »
Hereditary Hormone Excess: Genes, Molecular Pathways, and Syndromes.
S. J. Marx and W. F. Simonds (2005)
Endocr. Rev. 26, 615-661
   Abstract »    Full Text »    PDF »
Intracellular Kinase Inhibitors Selected from Combinatorial Libraries of Designed Ankyrin Repeat Proteins.
P. Amstutz, H. K. Binz, P. Parizek, M. T. Stumpp, A. Kohl, M. G. Grutter, P. Forrer, and A. Pluckthun (2005)
J. Biol. Chem. 280, 24715-24722
   Abstract »    Full Text »    PDF »
In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit.
A. S. Corbin, S. Demehri, I. J. Griswold, Y. Wang, C. A. Metcalf III, R. Sundaramoorthi, W. C. Shakespeare, J. Snodgrass, S. Wardwell, D. Dalgarno, et al. (2005)
Blood 106, 227-234
   Abstract »    Full Text »    PDF »
Autocrine- and paracrine-activated receptor tyrosine kinases in classic Hodgkin lymphoma.
C. Renne, K. Willenbrock, R. Kuppers, M.-L. Hansmann, and A. Brauninger (2005)
Blood 105, 4051-4059
   Abstract »    Full Text »    PDF »
Design of a Novel Class of Peptide Inhibitors of Cyclin-dependent Kinase/Cyclin Activation.
C. Gondeau, S. Gerbal-Chaloin, P. Bello, G. Aldrian-Herrada, M. C. Morris, and G. Divita (2005)
J. Biol. Chem. 280, 13793-13800
   Abstract »    Full Text »    PDF »
Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers.
H. Shigematsu, L. Lin, T. Takahashi, M. Nomura, M. Suzuki, I. I. Wistuba, K. M. Fong, H. Lee, S. Toyooka, N. Shimizu, et al. (2005)
J Natl Cancer Inst 97, 339-346
   Abstract »    Full Text »    PDF »
Somatic Mutations of the HER2 Kinase Domain in Lung Adenocarcinomas.
H. Shigematsu, T. Takahashi, M. Nomura, K. Majmudar, M. Suzuki, H. Lee, I. I. Wistuba, K. M. Fong, S. Toyooka, N. Shimizu, et al. (2005)
Cancer Res. 65, 1642-1646
   Abstract »    Full Text »    PDF »
Structural Basis of Constitutive Activity and a Unique Nucleotide Binding Mode of Human Pim-1 Kinase.
K. C. Qian, L. Wang, E. R. Hickey, J. Studts, K. Barringer, C. Peng, A. Kronkaitis, J. Li, A. White, S. Mische, et al. (2005)
J. Biol. Chem. 280, 6130-6137
   Abstract »    Full Text »    PDF »
Multidimensional Drug Profiling By Automated Microscopy.
Z. E. Perlman, M. D. Slack, Y. Feng, T. J. Mitchison, L. F. Wu, and S. J. Altschuler (2004)
Science 306, 1194-1198
   Abstract »    Full Text »    PDF »
The Three-dimensional Structure of the ZAP-70 Kinase Domain in Complex with Staurosporine: IMPLICATIONS FOR THE DESIGN OF SELECTIVE INHIBITORS.
L. Jin, S. Pluskey, E. C. Petrella, S. M. Cantin, J. C. Gorga, M. J. Rynkiewicz, P. Pandey, J. E. Strickler, R. E. Babine, D. T. Weaver, et al. (2004)
J. Biol. Chem. 279, 42818-42825
   Abstract »    Full Text »    PDF »

To Advertise     Find Products

Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882